This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (218)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Randomized Controlled Trial  • Choroidal Neovascularization  • Macular Degeneration  • Retinal/ Chorioretinal Disorders  • Alert me on articles by topic

Two-Year Results of 2 Randomized Clinical Trials—TAP Report 2

Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group

Arch Ophthalmol. 2001;119:198-207.

Objective  To report 24-month vision and fluorescein angiographic outcomes from trials evaluating photodynamic therapy with verteporfin (Visudyne; CIBA Vision Corp, Duluth, Ga) in patients with subfoveal choroidal neovascularization (CNV) caused by age-related macular degeneration (AMD).

Design  Two multicenter, double-masked, placebo-controlled, randomized clinical trials.

Setting  Twenty-two ophthalmology practices in Europe and North America.

Participants  Patients with subfoveal CNV lesions caused by AMD with greatest linear dimension on the retina measuring 5400 µm or less, with evidence of classic CNV and best-corrected visual acuity (approximate Snellen equivalent) between 20/40 and 20/200.

Methods  The methods were similar to those described in our 1-year results,¹ with follow-up examinations beyond 1 year continuing every 3 months (except for Photograph Reading Center evaluations, which occurred only at month 18 and month 24 examinations). During the second year, the same regimen (with verteporfin or placebo as applied at baseline) was used if angiography showed fluorescein leakage from CNV. The primary outcome was the proportion of eyes with fewer than 15 letters (approximately 3 lines) of visual acuity loss at the month 24 examination, adhering to an intent-to-treat analysis. The last observation was carried forward to impute for any missing data.

Results  Three hundred fifty-one (87%) of 402 patients in the verteporfin group compared with 178 (86%) of 207 patients in the placebo group completed the month 24 examination. Beneficial outcomes with respect to visual acuity and contrast sensitivity noted at the month 12 examination in verteporfin-treated patients were sustained through the month 24 examination. At the month 24 examination for the primary outcome, 213 (53%) of 402 verteporfin-treated patients compared with 78 (38%) of 207 placebo-treated patients lost fewer than 15 letters (P<.001). In subgroup analyses for predominantly classic lesions (in which the area of classic CNV makes up at least 50% of the area of the entire lesion) at baseline, 94 (59%) of 159 verteporfin-treated patients compared with 26 (31%) of 83 placebo-treated patients lost fewer than 15 letters at the month 24 examination (P<.001). For minimally classic lesions (in which the area of classic CNV makes up <50% but >0% of the area of the entire lesion) at baseline, no statistically significant differences in visual acuity were noted. Few additional photosensitivity adverse reactions and injection site adverse events were associated with verteporfin therapy in the second year of follow-up.

Conclusions  The visual acuity benefits of verteporfin therapy for AMD patients with predominantly classic CNV subfoveal lesions are safely sustained for 2 years, providing more compelling evidence to use verteporfin therapy for these cases. For AMD patients with subfoveal lesions that are minimally classic, there is insufficient evidence to warrant routine use of verteporfin therapy.

A complete list of the participants in the TAP Study Group is available in Arch Ophthalmol. 1999;117:1343-1344, with updates as of January 11, 2000, shown below.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Coagulation Gene Predictors of Photodynamic Therapy for Occult Choroidal Neovascularization in Age-Related Macular Degeneration
Parmeggiani et al.
IOVS 2008;49:3100-3106.
ABSTRACT | FULL TEXT  

Bevacizumab Treatment for Subfoveal Choroidal Neovascularization From Causes Other Than Age-Related Macular Degeneration
Chang et al.
Arch Ophthalmol 2008;126:941-945.
ABSTRACT | FULL TEXT  

Optical coherence tomography: limits of the retinal-mapping program in age-related macular degeneration
Krebs et al.
Br. J. Ophthalmol. 2008;92:933-935.
ABSTRACT | FULL TEXT  

Effect of Bevacizumab on Inflammation and Proliferation in Human Choroidal Neovascularization
Tatar et al.
Arch Ophthalmol 2008;126:782-790.
ABSTRACT | FULL TEXT  

A prospective randomised study on low-dose transpupillary thermotherapy versus photodynamic therapy for neovascular age-related macular degeneration
Odergren et al.
Br. J. Ophthalmol. 2008;92:757-761.
ABSTRACT | FULL TEXT  

Evaluation of the New Photosensitizer Stakel (WST-11) for Photodynamic Choroidal Vessel Occlusion in Rabbit and Rat Eyes
Berdugo et al.
IOVS 2008;49:1633-1644.
ABSTRACT | FULL TEXT  

Age-related macular degeneration: diagnosis and management
Cook et al.
Br Med Bull 2008;85:127-149.
ABSTRACT | FULL TEXT  

Simultaneous but Not Prior Inhibition of VEGF165 Enhances the Efficacy of Photodynamic Therapy in Multiple Models of Ocular Neovascularization
Ju et al.
IOVS 2008;49:662-670.
ABSTRACT | FULL TEXT  

Identifying Research Priorities: The Value of Information Associated with Repeat Screening for Age-Related Macular Degeneration
Bojke et al.
Med Decis Making 2008;28:33-43.
ABSTRACT  

Early Effects of Triamcinolone on Vascular Endothelial Growth Factor and Endostatin in Human Choroidal Neovascularization
Tatar et al.
Arch Ophthalmol 2008;126:193-199.
ABSTRACT | FULL TEXT  

The role of dynamic indocyanine green angiography in the diagnosis and treatment of retinal angiomatous proliferation
Bearelly et al.
Br. J. Ophthalmol. 2008;92:191-196.
ABSTRACT | FULL TEXT  

Histopathological findings in postmortem eyes after photodynamic therapy for choroidal neovascularisation in age-related macular degeneration: report of two cases
Kang et al.
Br. J. Ophthalmol. 2007;91:1602-1606.
ABSTRACT | FULL TEXT  

Suppression of Choroidal Neovascularization by Dendritic Cell Vaccination Targeting VEGFR2
Mochimaru et al.
IOVS 2007;48:4795-4801.
ABSTRACT | FULL TEXT  

Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration
Bashshur et al.
Arch Ophthalmol 2007;125:1357-1361.
ABSTRACT | FULL TEXT  

Polypoidal choroidal vasculopathy with an appearance similar to classic choroidal neovascularisation on fluorescein angiography
Iida
Br. J. Ophthalmol. 2007;91:1103-1104.
FULL TEXT  

Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degeneration
Cohen et al.
Br. J. Ophthalmol. 2007;91:1173-1176.
ABSTRACT | FULL TEXT  

Matrix metalloproteinases in human choroidal neovascular membranes excised following verteporfin photodynamic therapy
Tatar et al.
Br. J. Ophthalmol. 2007;91:1183-1189.
ABSTRACT | FULL TEXT  

The 100 Most Frequently Cited Articles in Ophthalmology Journals
Ohba et al.
Arch Ophthalmol 2007;125:952-960.
ABSTRACT | FULL TEXT  

Recurrence of choroidal neovascularisation after photodynamic therapy in patients with age-related macular degeneration
Potter and Szabo
Br. J. Ophthalmol. 2007;91:753-756.
ABSTRACT | FULL TEXT  

Correlation between Focal Macular Electroretinograms and Angiographic Findings after Photodynamic Therapy
Ishikawa et al.
IOVS 2007;48:2254-2259.
ABSTRACT | FULL TEXT  

Reduced Photoreceptor Damage after Photodynamic Therapy through Blockade of Nitric Oxide Synthase in a Model of Choroidal Neovascularization
She et al.
IOVS 2007;48:2268-2277.
ABSTRACT | FULL TEXT  

Two-year results of surgical removal of choroidal neovascular membranes related to non-age-related macular degeneration
Essex et al.
Br. J. Ophthalmol. 2007;91:649-654.
ABSTRACT | FULL TEXT  

Anxiety and Depression Prevalence Rates in Age-Related Macular Degeneration
Augustin et al.
IOVS 2007;48:1498-1503.
ABSTRACT | FULL TEXT  

Beta Carotene Supplementation and Age-Related Maculopathy in a Randomized Trial of US Physicians
Christen et al.
Arch Ophthalmol 2007;125:333-339.
ABSTRACT | FULL TEXT  

Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study
Chan et al.
Br. J. Ophthalmol. 2007;91:174-179.
ABSTRACT | FULL TEXT  

Effect of verteporfin photodynamic therapy on endostatin and angiogenesis in human choroidal neovascular membranes
Tatar et al.
Br. J. Ophthalmol. 2007;91:166-173.
ABSTRACT | FULL TEXT  

Public Health Impact of Neovascular Age-Related Macular Degeneration Treatments Extrapolated from Visual Acuity
Bandello et al.
IOVS 2007;48:96-103.
ABSTRACT | FULL TEXT  

New treatments for age-related macular degeneration
Imrie and Bailey
Age Ageing 2007;36:8-10.
FULL TEXT  

Neurotrophic Factors Minimize the Retinal Toxicity of Verteporfin Photodynamic Therapy
Paskowitz et al.
IOVS 2007;48:430-437.
ABSTRACT | FULL TEXT  

Triamcinolone acetonide suppresses early proangiogenic response in retinal pigment epithelial cells after photodynamic therapy in vitro
Obata et al.
Br. J. Ophthalmol. 2007;91:100-104.
ABSTRACT | FULL TEXT  

Dose-Ranging Study of Lutein Supplementation in Persons Aged 60 Years or Older
Rosenthal et al.
IOVS 2006;47:5227-5233.
ABSTRACT | FULL TEXT  

Different transitions of multifocal electroretinogram recordings between patients with age-related macular degeneration and polypoidal choroidal vasculopathy after photodynamic therapy
Imai et al.
Br. J. Ophthalmol. 2006;90:1524-1530.
ABSTRACT | FULL TEXT  

Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular Degeneration: Year 1 Results of the FOCUS Study.
Heier et al.
Arch Ophthalmol 2006;124:1532-1542.
ABSTRACT | FULL TEXT  

Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld et al.
NEJM 2006;355:1419-1431.
ABSTRACT | FULL TEXT  

Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown et al.
NEJM 2006;355:1432-1444.
ABSTRACT | FULL TEXT  

A Very Effective Treatment for Neovascular Macular Degeneration
Stone
NEJM 2006;355:1493-1495.
FULL TEXT  

Estimating the yearly number of eyes with treatable neovascular age-related macular degeneration using a direct standardization method and a markov model.
Korobelnik et al.
IOVS 2006;47:4270-4276.
ABSTRACT | FULL TEXT  

Intravitreal Bevacizumab for Choroidal Neovascularization Caused by AMD (IBeNA Study): Results of a Phase 1 Dose-Escalation Study.
Costa et al.
IOVS 2006;47:4569-4578.
ABSTRACT | FULL TEXT  

Some ethical considerations for the "off-label" use of drugs such as Avastin.
Wong and Kyle
Br. J. Ophthalmol. 2006;90:1218-1219.
FULL TEXT  

Evolving European guidance on the medical management of neovascular age related macular degeneration.
Chakravarthy et al.
Br. J. Ophthalmol. 2006;90:1188-1196.
ABSTRACT | FULL TEXT  

Phase I clinical trial results of verteporfin enhanced feeder vessel therapy in subfoveal choroidal neovascularisation in age related macular degeneration
Kozak et al.
Br. J. Ophthalmol. 2006;90:1152-1156.
ABSTRACT | FULL TEXT  

Photodynamic therapy for subfoveal choroidal neovascularisation in Vogt-Koyanagi-Harada disease
Nowilaty et al.
Br. J. Ophthalmol. 2006;90:982-986.
ABSTRACT | FULL TEXT  

Verteporfin photodynamic therapy induced apoptosis in choroidal neovascular membranes
Petermeier et al.
Br. J. Ophthalmol. 2006;90:1034-1039.
ABSTRACT | FULL TEXT  

Flavonoids protect human retinal pigment epithelial cells from oxidative-stress-induced death.
Hanneken et al.
IOVS 2006;47:3164-3177.
ABSTRACT | FULL TEXT  

Pegaptanib: A Novel Approach to Ocular Neovascularization
Chapman and Beckey
The Annals of Pharmacotherapy 2006;40:1322-1326.
ABSTRACT | FULL TEXT  

Lesion morphology in age-related macular degeneration and its therapeutic significance.
Beaumont and Kang
Arch Ophthalmol 2006;124:807-812.
ABSTRACT | FULL TEXT  

Consequences of verteporfin photodynamic therapy on choroidal neovascular membranes.
Tatar et al.
Arch Ophthalmol 2006;124:815-823.
ABSTRACT | FULL TEXT  

Occult With No Classic Subfoveal Choroidal Neovascular Lesions in Age-Related Macular Degeneration: Clinically Relevant Natural History Information in Larger Lesions With Good Vision From the Verteporfin in Photodynamic Therapy (VIP) Trial: VIP Report No. 4.
Writing Committee for the VIP Study Group
Arch Ophthalmol 2006;124:660-664.
ABSTRACT | FULL TEXT  

Sequenced combined intravitreal triamcinolone and indocyanine green angiography-guided photodynamic therapy for retinal angiomatous proliferation.
Freund et al.
Arch Ophthalmol 2006;124:487-492.
ABSTRACT | FULL TEXT  

Perspectives on verteporfin therapy combined with intravitreal corticosteroids.
Schmidt-Erfurth et al.
Arch Ophthalmol 2006;124:561-563.
FULL TEXT  

Should corticosteroids be considered as part of the standard care with photodynamic therapy?
Zarbin
Arch Ophthalmol 2006;124:563-571.
FULL TEXT  

Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study.
Chan et al.
Br. J. Ophthalmol. 2006;90:337-341.
ABSTRACT | FULL TEXT  

Iris Pigment Epithelial Translocation in the Treatment of Exudative Macular Degeneration: A 3-Year Follow-up.
Aisenbrey et al.
Arch Ophthalmol 2006;124:183-188.
ABSTRACT | FULL TEXT  

Long term results after transpupillary thermotherapy in eyes with occult choroidal neovascularisation associated with age related macular degeneration: a prospective trial
Stolba et al.
Br. J. Ophthalmol. 2006;90:158-161.
ABSTRACT | FULL TEXT  

Ultrahigh resolution optical coherence tomography in non-exudative age related macular degeneration
Pieroni et al.
Br. J. Ophthalmol. 2006;90:191-197.
ABSTRACT | FULL TEXT  

Influence of Treatment Parameters on Selectivity of Verteporfin Therapy
Michels et al.
IOVS 2006;47:371-376.
ABSTRACT | FULL TEXT  

Ocular Changes after Photodynamic Therapy
Tzekov et al.
IOVS 2006;47:377-385.
ABSTRACT | FULL TEXT  

Treatment of Retinal Angiomatous Proliferation in Age-Related Macular Degeneration: A Series of 104 Cases of Retinal Angiomatous Proliferation
Bottoni et al.
Arch Ophthalmol 2005;123:1644-1650.
ABSTRACT | FULL TEXT  

Retinal Anastomosis to Choroidal Neovascularization: A Bum Rap for a Difficult Disease
Bressler
Arch Ophthalmol 2005;123:1741-1743.
FULL TEXT  

Inflammatory Markers in Age-Related Maculopathy: Cross-sectional Analysis From the Muenster Aging and Retina Study
Dasch et al.
Arch Ophthalmol 2005;123:1501-1506.
ABSTRACT | FULL TEXT  

Complications After Photodynamic Therapy
Schnurrbusch et al.
Arch Ophthalmol 2005;123:1347-1350.
ABSTRACT | FULL TEXT  

Verteporfin Therapy for Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration: Four-Year Results of an Open-Label Extension of 2 Randomized Clinical Trials: TAP Report No. 7
Treatment of Age-Related Macular Degeneration With
Arch Ophthalmol 2005;123:1283-1285.
FULL TEXT  

Optical coherence tomography guided retreatment of photodynamic therapy
Krebs et al.
Br. J. Ophthalmol. 2005;89:1184-1187.
ABSTRACT | FULL TEXT  

Correlation of optical coherence tomography, with or without additional colour fundus photography, with stereo fundus fluorescein angiography in diagnosing choroidal neovascular membranes
Sandhu and Talks
Br. J. Ophthalmol. 2005;89:967-970.
ABSTRACT | FULL TEXT  

Macular Function after PDT in Myopic Maculopathy: Psychophysical and Electrophysiological Evaluation
Varano et al.
IOVS 2005;46:1453-1462.
ABSTRACT | FULL TEXT  

Verteporfin Therapy of Subfoveal Minimally Classic Choroidal Neovascularization in Age-Related Macular Degeneration: 2-Year Results of a Randomized Clinical Trial
Visudyne in Minimally Classic Choroidal Neovascula
Arch Ophthalmol 2005;123:448-457.
ABSTRACT | FULL TEXT  

Three Cases of Large Retinal Capillary Hemangiomas Treated With Verteporfin and Photodynamic Therapy
Aaberg et al.
Arch Ophthalmol 2005;123:328-332.
ABSTRACT | FULL TEXT  

Impact of lesion size on photodynamic therapy with verteporfin of predominantly classic lesions in age related macular degeneration
Arias et al.
Br. J. Ophthalmol. 2005;89:312-315.
ABSTRACT | FULL TEXT  

Optical coherence tomography in photodynamic therapy for subfoveal choroidal neovascularisation secondary to age related macular degeneration: a cross sectional study
Sahni et al.
Br. J. Ophthalmol. 2005;89:316-320.
ABSTRACT | FULL TEXT  

Photodynamic Therapy With Verteporfin: Observations on the Introduction of a New Treatment Into Clinical Practice
Schein et al.
Arch Ophthalmol 2005;123:58-63.
ABSTRACT | FULL TEXT  

Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration
Jonas et al.
Br. J. Ophthalmol. 2004;88:1557-1562.
ABSTRACT | FULL TEXT  

BDNF Reduces the Retinal Toxicity of Verteporfin Photodynamic Therapy
Paskowitz et al.
IOVS 2004;45:4190-4196.
ABSTRACT | FULL TEXT  

CAI Is a Potent Inhibitor of Neovascularization and Imparts Neuroprotection in a Mouse Model of Ischemic Retinopathy
Franklin et al.
IOVS 2004;45:3756-3766.
ABSTRACT | FULL TEXT  

A prospective study of visual function and quality of life following PDT in patients with wet age related macular degeneration
Armbrecht et al.
Br. J. Ophthalmol. 2004;88:1270-1273.
ABSTRACT | FULL TEXT  

Choroidal Neovascularization After Central Retinal Vein Occlusion in a 47-Year-Old Man
DiLoreto et al.
Arch Ophthalmol 2004;122:1398-1401.
FULL TEXT  

Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case
Smith et al.
Br. J. Ophthalmol. 2004;88:1107-1112.
ABSTRACT | FULL TEXT  

Colour vision testing as an aid to diagnosis and management of age related maculopathy
Arden and Wolf
Br. J. Ophthalmol. 2004;88:1180-1185.
ABSTRACT | FULL TEXT  

Expression of Leukocyte Adhesion Molecules in Human Subfoveal Choroidal Neovascular Membranes Treated with and without Photodynamic Therapy
Yeh et al.
IOVS 2004;45:2368-2373.
ABSTRACT | FULL TEXT  

Selective Photodynamic Therapy by Targeted Verteporfin Delivery to Experimental Choroidal Neovascularization Mediated by a Homing Peptide to Vascular Endothelial Growth Factor Receptor-2
Renno et al.
Arch Ophthalmol 2004;122:1002-1011.
ABSTRACT | FULL TEXT  

Subthreshold Transpupillary Thermotherapy Reduces Experimental Choroidal Neovascularization in the Mouse without Collateral Damage to the Neural Retina
Ming et al.
IOVS 2004;45:1969-1974.
ABSTRACT | FULL TEXT  

Treatment of age-related macular degeneration
Browning et al.
JRSM 2004;97:166-169.
FULL TEXT  

Photodynamic Therapy for Occult Choroidal Neovascularization With Pigment Epithelium Detachment in Age-Related Macular Degeneration
Axer-Siegel et al.
Arch Ophthalmol 2004;122:453-459.
ABSTRACT | FULL TEXT  

Prevalence of Age-Related Macular Degeneration in the United States
The Eye Diseases Prevalence Research Group
Arch Ophthalmol 2004;122:564-572.
ABSTRACT | FULL TEXT  

Age-Related Macular Degeneration: Treating the Whole Patient
Tasman and Rovner
Arch Ophthalmol 2004;122:648-649.
FULL TEXT  

Natural History of Minimally Classic Subfoveal Choroidal Neovascular Lesions in the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Investigation: Outcomes Potentially Relevant to Management--TAP Report No. 6
Bressler et al.
Arch Ophthalmol 2004;122:325-329.
ABSTRACT | FULL TEXT  

Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration
Rechtman et al.
Br. J. Ophthalmol. 2004;88:344-347.
ABSTRACT | FULL TEXT  

The Complications of Age-Related Macular Degeneration Prevention Trial (CAPT): rationale, design and methodology
The Complications of Age-Related Macular Degenerat
Clin Trials 2004;1:91-107.
ABSTRACT  

Inhibition of Choroidal Neovascularization in Rats by the Urokinase-Derived Peptide A6
Koh et al.
IOVS 2004;45:635-640.
ABSTRACT | FULL TEXT  

Clinicopathological findings of choroidal neovascularisation following verteporfin photodynamic therapy
Gelisken et al.
Br. J. Ophthalmol. 2004;88:207-211.
ABSTRACT | FULL TEXT  

Photodynamic therapy with verteporfin is effective, but how big is its effect? Results of a systematic review
Meads and Hyde
Br. J. Ophthalmol. 2004;88:212-217.
ABSTRACT | FULL TEXT  

Verteporfin and myocardial infarction
Schattner and Pollack
The Annals of Pharmacotherapy 2004;38:352-352.
FULL TEXT  

Photodynamic Therapy With Verteporfin in Subfoveal Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy
Ergun et al.
Arch Ophthalmol 2004;122:37-41.
ABSTRACT | FULL TEXT  

Autologous peripheral retinal pigment epithelium translocation in patients with subfoveal neovascular membranes
van Meurs et al.
Br. J. Ophthalmol. 2004;88:110-113.
ABSTRACT | FULL TEXT  

Palladium-103 plaque radiation therapy for macular degeneration: results of a 7 year study
Finger et al.
Br. J. Ophthalmol. 2003;87:1497-1503.
ABSTRACT | FULL TEXT  

Exudative Complications After Photodynamic Therapy
Holz et al.
Arch Ophthalmol 2003;121:1649-1652.
FULL TEXT  

Influence of Photodynamic Therapy on Expression of Vascular Endothelial Growth Factor (VEGF), VEGF Receptor 3, and Pigment Epithelium-Derived Factor
Schmidt-Erfurth et al.
IOVS 2003;44:4473-4480.
ABSTRACT | FULL TEXT  

Blood Pressure, Atherosclerosis, and the Incidence of Age-Related Maculopathy: The Rotterdam Study
van Leeuwen et al.
IOVS 2003;44:3771-3777.
ABSTRACT | FULL TEXT  

Relationship between Refraction and Prevalent as well as Incident Age-Related Maculopathy: The Rotterdam Study
Ikram et al.
IOVS 2003;44:3778-3782.
ABSTRACT | FULL TEXT  

Photodynamic Therapy of Subfoveal Choroidal Neovascularization With Verteporfin: Fluorescein Angiographic Guidelines for Evaluation and Treatment--TAP and VIP Report No. 2
Treatment of Age-Related Macular Degeneration With
Arch Ophthalmol 2003;121:1253-1268.
ABSTRACT | FULL TEXT  

Photodynamic therapy for recurrent myopic choroidal neovascularisation after limited macular translocation surgery
Chan et al.
Br. J. Ophthalmol. 2003;87:1188-1189.
FULL TEXT